Literature DB >> 15655098

Primary systemic vasculitis: clinical features and mortality.

S E Lane1, R A Watts, L Shepstone, D G I Scott.   

Abstract

BACKGROUND: Wegener's granulomatosis (WG), Churg Strauss syndrome (CSS) and microscopic polyangiitis (MPA) are primary systemic vasculitides (PSV), the clinical features of which have been described from tertiary centres. AIM: To provide the first clinical description of MPA from a general hospital and compare clinical features with WG and CSS.
DESIGN: Retrospective analysis of patient records.
METHODS: Records of 99 PSV patients attending a single hospital, from 1988 to 2000, were reviewed for: clinical features, date/age at diagnosis, sex, duration of illness, anti-neutrophil cytoplasmic antibodies (ANCA), treatment, comorbidity and deaths. Cases were classified using ACR, CHCC and Lanham criteria/definitions. Birmingham vasculitis activity scores (BVAS) and damage index (VDI) were calculated. Survival was assessed using Cox proportional hazards model and standardized mortality ratios (SMRs).
RESULTS: Compared to previous reports there was more ENT (29%) and respiratory (29%) but less renal (92%) involvement in MPA, and less ENT involvement in WG (81%). CSS showed high neurological (72%), cardiovascular (28%) and gastrointestinal (17%) involvement and the highest median (range) VDI (p = 0.01 vs. WG; p = 0.001 vs. MPA). BVAS1 was significantly lower in MPA than in WG [median (range) 15 (4-29) vs. 21 (6-39), (p = 0.001)] but not in CSS [20 (7-28), p = 0.08]. SMR (95%CI) for PSV was 4.8 (3.0-6.6); 5-year survival was 45.1% for MPA, 75.9% for WG and 68.1% for CSS. Age was a significant risk, but only to the same extent as in the reference population. When age was adjusted for, no other significant factor was found. DISCUSSION: The clinical characteristics seen here are similar to those in previous series. There are difficulties in using the MPA CHCC definitions in classification. There is a high proportion of neurological involvement in CSS, causing permanent damage. MPA may have a poorer prognosis than WG or CSS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655098     DOI: 10.1093/qjmed/hci015

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  42 in total

Review 1.  ANCA-associated vasculitides-lessons from the adult literature.

Authors:  Joannis Vamvakopoulos; Caroline O Savage; Lorraine Harper
Journal:  Pediatr Nephrol       Date:  2010-04-01       Impact factor: 3.714

2.  Infective endocarditis with multiple mycotic aneurysms mimicking vasculitis: A case report.

Authors:  Ji Hyeon Park; Hye Ryoun Jang; Jung Eun Lee; Wooseong Huh; Dae Joong Kim; Ha Young Oh; Yoon-Goo Kim
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

3.  Diagnosis and treatment of cerebral vasculitis.

Authors:  Peter Berlit
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 4.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 5.  Development of comprehensive disease assessment in systemic vasculitis.

Authors:  Oliver Flossmann; Paul Bacon; Kirsten de Groot; David Jayne; Niels Rasmussen; Philip Seo; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

6.  Estimation of BVAS in patients with microscopic polyangiitis in Japan.

Authors:  Mitsuyo Itabashi; Takashi Takei; Taku Morito; Yasuko Yabuki; Hitoe Suzuki; Minoru Ando; Mayuko Akamatsu; Mayuko Yamazaki; Michihiro Mitobe; Yoshihiko Watanabe; Takahiro Mochizuki; Kosaku Nitta
Journal:  Clin Rheumatol       Date:  2011-09-02       Impact factor: 2.980

7.  Clinical outcomes of ANCA-associated vasculitis in elderly patients.

Authors:  Ágnes Haris; Kálmán Polner; József Arányi; Henrik Braunitzer; Ilona Kaszás; István Mucsi
Journal:  Int Urol Nephrol       Date:  2014-04-23       Impact factor: 2.370

8.  ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity.

Authors:  Antoine G Sreih; Ranadeep Mandhadi; Fadi Aldaghlawi; Asad Khan; Vajiha Irshad; Katherine Finn; Joel A Block
Journal:  Clin Rheumatol       Date:  2014-04-22       Impact factor: 2.980

9.  AP-VAS 2012 case report: a case of myeloperoxidase antineutrophil cytoplasmic antibody-positive microscopic polyangiitis with rapidly progressive glomerulonephritis and hearing loss.

Authors:  Maki Tsukamoto; Seiichiro Shimizu; Megumi Koizumi; Nobuo Kitahara; Yoshihiro Ohtaki; Shigeyuki Aoki; Hiroshi Miyakawa
Journal:  CEN Case Rep       Date:  2013-01-30

Review 10.  The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis.

Authors:  Lisa C Willcocks; Paul A Lyons; Andrew J Rees; Kenneth G C Smith
Journal:  Arthritis Res Ther       Date:  2010-02-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.